Exclusivity is the holy grail of product development, whether the product is branded or similar. But achieving exclusivity, and with it your client’s and management’s goals, involves understanding a complex web of national and international IP and regulatory laws. Our panel will discuss the different types of exclusivities, their interplay and role in product development, and implications along the spectrum from development or acquisition to similar challenge and beyond.
Panel Moderator: Jeremiah B. Frueauf, Director
Panelist: John M. Covert, Director
Panelist: Carla Kim, Director
Panelist: Paul Golian, Vice President & Assistant General Counsel, Bristol-Myers Squibb
Panelist: Alan Koller, Ph.D., Chief Patent Counsel, Purdue Pharma LP